2月5日，恒瑞醫藥（600276/01276）發布公告，公司子公司蘇州盛迪亞生物醫藥有限公司收到國家藥品監督管理局覈准簽發關於SHR-1894注射液的《藥物臨床試驗批准通知書》，將於近期開展臨床試驗。 該藥物是公司自主研發的治療用生物製品，預期可在特應性皮炎治療中發揮保護皮膚屏障和抑制炎症的作用。目前國內外尚無同類藥物獲批上市。 截至目前，SHR-1894注射液相關項目累計研發投入約為4010...
網頁鏈接
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
精彩評論